$Aldeyra Therapeutics (ALDX.US)$Reuters· 1 min ago Aldeyra Therapeutics Receives Complete Response Letter From the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease
Trytosaveabit
OPRhino12
:
Bad news short term! They will resubmit again in few months! But im sure this will crash the price today! But that crash could be a overreaction and be a buy opportunity once it hits bottom? JMO
NOTE! 1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice. 2. Do NOT open position WITHOUT chart confirmation, indicators, momentum. 3. Scale out and secure profits. 4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability. 5. I DO NOT give buy or sell advice 6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow) 7. NEVER be a blind follower. LASTLY, If ...
Jaguar8
OPMangkawat
:
Termination of loan may impact their financial status that is why they filed another prospectus. This is just possible scalp play for me IMO
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Aldeyra Therapeutics Stock Forum
I miss it
FDA Denial Forces Aldeyra Back to Trials: Key Details on $101M Cash Position and 2025 Resubmission Plan
Aldeyra Therapeutics Receives Complete Response Letter From the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If ...
No comment yet